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Abstract. A 71-year-old woman with arthralgia and lung 
fibrosis was referred to Mito Kyodo General Hospital 
(Mito, Japan) for a mass, which was incidentally observed 
on a chest radiograph. The chest computed tomography 
scan demonstrated fibrotic lesions in the lower lobes of the 
lung and a nodule in the left upper lobe. The serum levels 
of myeloperoxidase (MPO)-anti-neutrophil cytoplasmic 
antibody (ANCA) and proteinase 3 (PR3)-ANCA were 
60.3 and 7.5 U/ml, respectively. A transbronchial biopsy 
obtained from the nodule in the left upper lobe of the lung 
revealed a lung adenocarcinoma and the patient underwent 
standard upper lobectomy of the left lung. Subsequent to the 
resection, the serum levels of PR3-ANCA and MPO-ANCA 
returned to 10.0 and <1.0 U/ml, respectively. Notably, titers of 
antinuclear antibodies were also decreased during the post-
operative course. Although elevated serum ANCA levels are 
rarely seen in lung cancer, they may be associated with the 
occurrence of lung cancer in certain patients, as observed in 
the present case.
Introduction
Anti-neutrophil cytoplasmic antibodies (ANCAs) are 
autoantibodies produced by the immune system, which 
mistakenly target and attack proteins within an individual's 
neutrophils (1). Using indirect f luorescence antibody 
testing, ANCAs are typically classified as either myelo-
peroxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA 
and atypical-ANCA (1). The clinical significance of the 
two common types or ANCA subsets, MPO-ANCA and 
PR3-ANCA, differs; MPO-ANCA is often associated with 
microscopic polyarteritis, necrotizing glomerulonephritis 
and Churg-Strauss syndrome, whereas PR3-ANCA is 
found primarily in patients exhibiting granulomatosis with 
polyangiitis (previously Wegener's granulomatosis) (1). The 
association between MPO-ANCA and lung fibrosis has also 
been demonstrated (2,3). The present case report describes 
a patient with elevated serum levels of MPO-ANCA and 
PR3-ANCA, which decreased during the postoperative 
course. To the best of our knowledge, this is the first case to 
show a decrease in elevated serum levels of the two types of 
ANCA following treatment for lung cancer.
Case report
A 71-year-old woman with arthralgia and lung fibrosis was 
referred to Mito Kyodo General Hospital (Mito, Japan) for a 
mass that was incidentally observed on a chest radiograph. 
The chest radiograph and a computed tomography scan 
showed ground-glass opacity and honeycombing in the lower 
lobes of the lungs, and a nodule in the left upper lobe of the 
lung (Figs. 1 and 2). The differential diagnosis was primary 
lung cancer and a nodule with granulomatosis with polyangiitis. 
Laboratory analysis demonstrated antinuclear antibodies were 
positive with a titer of 1:160 homogenous pattern, and a titer 
of 1:160 speckled pattern. Serum levels of MPO-ANCA and 
PR3-ANCA were elevated to 60.3 and 7.5 U/ml, respectively 
(normal range, ≤3.5 IU/ml). A transbronchial biopsy obtained 
from the lesion revealed a lung adenocarcinoma and the 
patient underwent standard upper lobectomy of the left lung. 
Written informed consent was obtained from the patient. The 
postoperative period was not eventful and the postoperative 
diagnosis was pT3N1M0, stage IIIA (according to the seventh 
edition of the International Union Against Cancer TNM 
Staging System for Lung Cancer), epidermal growth factor 
receptor mutation-negative and anaplastic lymphoma receptor 
tyrosine kinase-negative fusion gene. One month subsequent to 
the resection, MPO-ANCA and PR3-ANCA serum levels had 
returned to 10.0 and <1.0 U/ml, respectively. Antinuclear anti-
bodies were positive, with a titer of 1:80 homogenous pattern 
and a titer of 1:80 speckled pattern. The patient experienced 
an uneventful postoperative course for 6 months; however, 
developed lung and brain metastases, and succumbed due to 
lung cancer 15 months after surgery.
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Discussion
The presence of antibodies that react with neutrophil cyto-
plasm in patients who had necrotizing glomerulonephritis 
and small-vessel vasculitis was first reported by Davies et al 
in 1982 (4). A wide variety of pulmonary abnormalities, 
including alveolar hemorrhage and pulmonary fibrosis, have 
been reported to be associated with MPO-ANCA (5-7). 
Whereas the majority of patients with granulomatosis with 
polyangiitis have elevated serum levels of PR3-ANCA (8,9). It 
currently remains unknowns as to whether there is a definite 
association between solid tumors and elevated serum levels 
of ANCAs. Edgar et al (10) were the first to report an asso-
ciation between solid tumors and ANCA-associated vasculitis. 
Thereafter, Tatsis et al (11) evaluated the frequencies and types 
of malignant diseases occurring before or simultaneously with 
the diagnosis of patients positive for PR3-ANCA. The authors 
reported that 23 of 477 patients that were PR3-ANCA-positive 
had solid tumors; the most common malignant disease was 
renal cell carcinoma and one patient had lung cancer (11). 
Including this patient, to the best of knowledge, there have been 
four ANCA-positive lung cancer patients (Table I) (10-13). The 
patients were the fifth and sixth decades, and were all male. 
Three of the patients were positive for PR3-ANCA, and the 
others were positive for MPO-ANCA. Two patients presented 
with squamous cell carcinoma, and one patient had adenocar-
cinoma (and there was no description for one patient). Two 
patients had renal impairment, but none of the patients had 
pulmonary fibrosis. The patient in the current study complained 
of arthralgia for 5 years and lung fibrosis was detected on a 
chest radiograph taken 2 years before referral to our depart-
ment. Elevated serum levels of MPO-ANCA may be associated 
with lung fibrosis in this patient. As the patient presented 
with a mass on the chest radiograph, measurement of serum 
PR3-ANCA levels was performed to rule out the possibility of 
developing granulomatosis with polyangiitis. Notably, in the 
present case, elevated PR3-ANCA and MPO-ANCA serum 
levels were noted pretreatment, and decreases in the levels 
of the two types of ANCA were observed postoperatively. 
Furthermore, titers of antinuclear antibodies were observed to 
decrease during the postoperative course. As shown in Table I, 
decreases in the elevated serum levels of either MPO-ANCA 
or PR3-ANCA following therapy for lung cancer were reported 
in two patients (12,13). Navarro et al (12) reported a case of 
lung adenocarcinoma with elevated MPO-ANCA serum levels 
and its decrease as a result of therapy for lung cancer with 
prednisolone and cyclophosphamide. Morisako et al (13) 
reported a case with elevated levels of PR3-ANCA in a patient 
Figure 1. Chest radiograph demonstrating ground-glass opacitiy and honey-
combing in the lower lobes of the lung.
Figure 2. Chest computed tomography scan demonstrating a nodule in the 
left upper lobe of the lung (arrows).
Table I. ANCA-positive lung cancer patients.
        ANCA
 Age    Renal  Lung cancer improvement
Author, year (Refs.) (years) Gender ANCA-positive Pathology impairment IPF therapy post-treatment
Edgar et al, 1993 (10) 62 M PR3-ANCA SQ Present ND BSC ND
Tatsis et al, 1999 (11) 63 M PR3-ANCA ND ND ND ND ND
Navarro et al, 1994 (12) 68 M MPO-ANCA AD Present ND Irradiation Present
Morisako et al, 2006 (13) 57 M PR3-ANCA SQ Absent Absent Chemotherapy Present
Present case 70 F PR3-ANCA AD Absent Present Surgery Present
   MPO-ANCA
ANCA, anti-neutrophil cytoplasmic antibodies; M, male; F, female; PR3, proteinase 3; MPO, myeloperoxidase; SQ, squamous cell lung cancer; AD, 
adenocarcinoma of the lung; ND, not described; IPF, idiopathic pulmonary fibrosis; BSC, best supportive care.
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with advanced squamous cell lung carcinoma, and the ANCA 
level was decreased subsequent to successful chemotherapy. 
However, to the best of our knowledge, the present case is the 
first to exhibit decreases in elevated serum levels of the two 
types of ANCA due to therapy for lung cancer. In certain cases 
of ANCA-associated vasculitis, malignant disease may be a 
trigger for either the generation of ANCAs or the develop-
ment of vasculitis (10). In conclusion, together with the results 
of previously reported cases (12,13), elevated serum ANCA 
levels may be associated with the existence of malignant 
disease, although the occurrence of the two types of ANCA 
being elevated is rare. The present case provides information, 
which may facilitate the diagnosis and treatment of similar 
cases of patients presenting with these diseases.
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